Menu

PNAS to Stop Publishing Its Print Edition in 2019

The move to online-only will allow for articles to be longer in length.

Sep 7, 2018
Kerry Grens

ABOVE: © ISTOCK, ONURDONGEL

PNAS announced on Twitter this week (September 5) that the publication would discontinue its print edition come January, and in July 2019, the journal will extend the page limit on manuscripts.

“Eliminating our strict sizing requirements will simplify the author submission and publication process, addressing a common complaint about submitting to PNAS,” Taylor Gedeon, a media coordinator at the journal, tells The Scientist in an email. 

PNAS has had a six-page maximum, but in July will allow authors to go up to 12 pages for an additional fee. “Flexible article length is more in line with the majority of scientific journals, which do not enforce rigid page limits, and which charge an additional fee for articles exceeding a standard length,” Gedeon writes. Papers will not be able to go beyond 12 pages.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!